Therapeutic options in thymomas and thymic carcinomas

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Oncology

Background:

• Thymic malignancies are rare, with surgery as the primary curative treatment.
• Advanced or recurrent thymic cancers often necessitate palliative chemotherapy or radiotherapy.
• Evidence for treatment efficacy and safety is primarily from small Phase 2 trials and retrospective studies.

Purpose of the Study:

• To comprehensively review current and emerging treatment strategies for thymic malignancies.
• To discuss management of specific clinical scenarios including metastasis and paraneoplastic syndromes.
• To highlight advancements in pharmacotherapy for thymic cancers.

Main Methods:

• Systematic review of treatment modalities for thymic malignancies.
• Inclusion of surgical, radiotherapeutic, and pharmacotherapeutic approaches.
• Analysis of cytotoxic chemotherapy, molecular-targeted therapy, and immunotherapy.

Main Results:

• Cytotoxic chemotherapy remains a standard pharmacotherapy option.
• Molecular-targeted agents (sunitinib, lenvatinib) and immune checkpoint inhibitors (pembrolizumab) show potential for thymic carcinomas.
• Ongoing trials are investigating combination therapies like lenvatinib plus pembrolizumab.

Conclusions:

• While surgery is optimal, advanced thymic malignancies require multimodal treatment.
• Emerging targeted therapies and immunotherapies offer new avenues for thymic carcinoma treatment.
• Combination pharmacotherapy strategies are anticipated to improve disease control for thymic malignancies.